Document:

<Page>

                                                             EXHIBIT NO. 10.57

          CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
         SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS.

                          TRAINING & LICENSE AGREEMENT

     This License Agreement (hereinafter referred to as the "Agreement"),
effective as of the 18th day of December, 2002 (hereinafter referred to as the
"Effective Date") is by and between Becton, Dickinson and Company, having a
place of business at 7 Loveton Circle, Sparks, Maryland 21152-0999 (hereinafter
referred to as "BD"), and Genaissance Pharmaceuticals, Inc. (GNSC), having a
place of business at Five Science Park, New Haven, CT 06511 (hereinafter
referred to as "GNSC").

                                   WITNESSETH

     WHEREAS, GNSC is interested in researching and developing certain
diagnostic technologies by utilizing BD's proprietary BDProbeTec(TM) ET platform
and BD's proprietary SDA Technology;

     WHEREAS, BD is interested in entering into an agreement with GNSC to train
GNSC in the utilization of BD's proprietary BDProbeTec(TM) ET platform; and to
grant GNSC a non-exclusive license to BD's proprietary SDA technology and BD's
proprietary Intellectual Property necessary for operation of the BDProbeTec ET.

     NOW, THEREFORE, in consideration of the premises and the mutual promises
and covenants herein contained, BD and GNSC agree as follows:

1.   DEFINITIONS

   a)  "Licensed Patents" shall mean the U.S. patents and pending U.S. patent
       applications listed in Appendix A to this Agreement, and any re-issues,
       divisionals, continuations, re-examinations and foreign counter-parts
       thereof.

   b)  "Licensed Know-How" shall mean BD's know-how related to Licensed Patents,
       the BDProbeTec(TM) ET, and custom software for the BDProbeTec(TM) ET.
       Licensed Know-How shall also include, upon written request from GNSC,
       BD's know-how necessary in the design and development of assays that
       utilize BDProbeTec(TM) ET. Licensed Know-How shall further include
       methods to conduct research to design and develop assays for qualitative
       detection of nucleic acids through SDA Technology and homogeneous nucleic
       acid detection. Licensed Know-How shall additionally include any and all
       information and discussions under Section 2.

   c)  "Licensed Products" shall mean any device, instrument, service, kit,
       composition of matter, material, product or component thereof that
       utilizes Licensed Know-How, or the making, using, selling or importing of
       which would, in the absence of the license granted hereunder, infringe,
       contribute to the infringement of, or induce the infringement of any
       claim to a Licensed Patent. For purposes of this Agreement, the

                                        1
<Page>

       term "Licensed Product" shall include products listed in Appendix C to be
       added thereto upon initiation of development of each product covered by
       this Agreement.

   d)  "HAP(TM) Marker" shall mean a polymorphism or any ordered combination of
       two or more polymorphisms present at a locus on a single chromosome [**].

   e)  "Predictive HAP(TM) Marker" shall mean a HAP(TM) Marker that is
       associated with a clinical endpoint [**].

   f)  "HAP(TM) Partner(s)" shall mean a Third Party, other than a diagnostic
       company, with whom GNSC agrees to provide genotype data or genetic
       testing services tied to a specific product development program.

   g)  "BDProbeTec(TM) ET" shall mean the clinical platform for infectious
       disease testing owned by BD using SDA Technology and real time detection
       means.

   h)  "Strand Displacement Amplification Technology" or "SDA Technology" shall
       mean an isothermal method of amplifying DNA using a restriction enzyme
       with the capability to nick a recognition site and a polymerase to
       initiate synthesis of a new strand of DNA and displace a strand of DNA
       that has annealed to the target and which is described in further detail
       in the patents set forth in Appendix A.

   i)  "Instrument" shall mean the BDProbeTec(TM) ET installed in GNSC's HAP(TM)
       Typing facility in New Haven, CT.

   j)  "Net Sales" shall mean a Licensed Product which is sold, leased, put into
       use or otherwise placed in commerce by GNSC. No deduction shall be made
       for taxes, duties, levies and similar charges (and any related interest
       and penalties), however designated, imposed as a result of the existence
       or operation of this Agreement.

   k)  "Intellectual Property" shall mean any new patentable and unpatentable
       inventions, discoveries, improvements, biological materials, software,
       know-how, copyrightable material and any equivalents thereof.

   l)  "Confidential Information" shall mean any information which is deemed to
       be proprietary and confidential to the Party which owns that information.

   m)  "Quarter" shall mean any period of three consecutive calendar months
       beginning January 1, April 1, July 1, and October 1, occurring during the
       term of this Agreement.

   n)  "Party" shall mean BD or GNSC.

   o)  "Third Party" shall mean any party other than BD or GNSC.

   p)  "Test" shall mean one or more HAP(TM) Marker(s) that collectively give a
       phenotypic result.

                                        2
<Page>

2.   TRAINING OF GNSC

   a)  Within six (6) weeks of the Effective Date of this Agreement, BD shall
       provide a training program to GNSC personnel for utilization of the
       BDProbeTec(TM) ET and the Licensed Know-How and technology relating to
       the Licensed Patents. The training shall involve direct contact between
       BD and GNSC scientists to discuss the Licensed Know-How and technology
       relating to the Licensed Patents. The BD and GNSC personnel shall
       discuss, generally, methods of assay discovery and development. However,
       the training shall not suggest specific areas of research. The training
       plan is set forth in Appendix B.

   b)  GNSC hereby acknowledges and agrees that:

     i)   BD is a manufacturer of in-vitro diagnostic (IVD) devices and assays,

     ii)  BD is strictly prohibited from collaborating or participating in the
          design and development of tests except in compliance with the
          requirements of the Food and Drug Administration, and

     iii) none of the assays discussed during the training may be used for
          diagnostic purposes unless such assays are submitted to the FDA for
          clearance or are otherwise in compliance with FDA requirements.

   c)  Following the training under this Section 2, GNSC shall have full
       responsibility for its activities under this Agreement without any
       further training assistance from BD.

3.   TESTING OF BDPROBETEC(TM) ET BY GNSC

   a)  Within [**] of the Effective Date of this Agreement, BD shall install the
       Instrument at GNSC's facility in New Haven, CT, [**]. This installation
       shall include field service of the Instrument. The Instrument shall
       remain the property of BD. An additional Instrument may also be
       installed, [**] upon mutual written agreement between BD and GNSC.

   b)  Upon written request by GNSC, BD shall provide information on existing
       software code and communication code to aid GNSC in their development of
       external applications for processing and analysis of data from
       BDProbeTec(TM) ET. Such information shall be treated as Confidential
       Information as set forth in Section 9.

   c)  GNSC shall test the ability of the BDProbeTec(TM) ET to meet certain
       performance requirements as defined by GNSC.

   d)  Within [**] of installation of the BDProbeTec(TM) ET, GNSC shall provide
       BD with a written report detailing the test resultS, as well as any
       suggestions for improving the operation or performance of the
       BDProbeTec(TM) ET.

                                        3
<Page>

   e)  If the test results meet GNSC's performance requirements, GNSC shall
       adopt the BDProbeTec(TM) ET as a platform for the purpose of internal
       research and development of assays and for commercialization consistent
       with Section 4 of this Agreement.

   f)  If GNSC's test results do not meet its performance requirements, then
       [**], shall either (i) [**] and GNSC shall repeat the test described in
       this paragraph 3, or (ii) remove the Instrument from GNSC. If BD chooses
       to remove Instrument, this Agreement shall terminate and GNSC may seek
       other alternative technologies of its own choosing at its own cost and
       GNSC shall return all reagents to BD.

   g)  BD shall provide, [**] to GNSC, reagents and supplies that are sold by BD
       for GNSC's use with the BDProbeTec(TM) ET, [**] fOr GNSC to develop,
       design, optimize and validate assays for internal research and
       development purposes of GNSC or HAP(TM) Partners, [**]. GNSC shall
       provide or obtain all other needed reagents and supplies [**].

   h)  BD shall also install at GNSC's facility in New Haven, CT updates to the
       Instrument and associated software within [**] after they become
       commercially available during the Term, [**].

4.   LICENSE GRANT

   a)  BD hereby grants to GNSC a non-exclusive, fully paid-up, non-transferable
       license, without the right to sublicense, to Licensed Patents and
       Licensed Know-How to use the Instrument solely for the internal research
       and development activities stated in Sections 2 and 3 above. This license
       is limited to the territory of the United States of America. The fields
       of [**] from this license.

   b)  BD hereby grants to GNSC a world-wide, non-exclusive, royalty-bearing,
       non-transferable license, without the right to sublicense, to make, use,
       sell, offer for sale and import Licensed Products for genotyping HAP(TM)
       Markers in all fields [**]. Excluded from this grant is the right to
       make, sell, offer for sale or import the BD ProbeTec(TM) ET.

   c)  GNSC shall restrict the knowledge and use of the the Licensed Know-How
       granted under this Section 4 to only GNSC employees who are on a
       need-to-know basis and such GNSC employees shall maintain the
       confidentiality of the Licensed Know-How pursuant to Section 9.

5.   INTELLECTUAL PROPERTY

   a)  BD shall own:

     i)   all BD Intellectual Property created before the Effective Date, and

     ii)  all Intellectual Property created pursuant to activities under this
          Agreement that relates to Licensed Patents, Licensed Know-How, SDA
          Technology or BD ProbeTec(TM) ET .

                                        4
<Page>

   b)  GNSC shall own:

     i)   all GNSC Intellectual Property created before the Effective Date, and

     ii)  all Intellectual Property created pursuant to activities under this
          Agreement that relates to HAP(TM) Markers and Predictive HAP(TM)
          Markers including assays, subject to the terms of GNSC's agreements
          with its HAP(TM) Partners.

   c)  Any Intellectual Property created under Sections 5.a.ii or 5.b.ii shall
       be treated as Confidential Information by the non-owning party as set
       forth in Section 9. Each party shall promptly give notice under Section
       14 to the other party of any Intellectual Property subject to Sections
       5.a.ii or 5.b.ii.

6.   ROYALTIES

   a)  In consideration of the license granted hereunder, GNSC shall pay BD a
       royalty rate of [**] ([**]%) percent on Net Sales of Licensed Products on
       or subsequent to the Effective Date, [**].

7.   REPORTS AND PAYMENTS

   a)  GNSC shall submit to BD within [**] days after the end of each Quarter
       during the term of this Agreement, and upon the termination of this
       Agreement, separate written reports for the preceding three month period
       identifying Net Sales of Licensed Products, and the amount of royalty due
       BD together with payment of such royalty amount or any other payments. If
       no royalties or payments are due to BD for any reporting period, the
       report shall so state.

   b)  All royalties or other payments due hereunder shall be payable in US
       dollars. Any conversion to US dollars shall be converted monthly at the
       prevailing rate as quoted in the Wall Street Journal for the last day of
       each month.

   c)  GNSC shall keep full, clear and accurate records showing all sales of
       Licensed Products and all Net Sales of Licensed Products. GNSC shall
       retain such records for at least seven (7) years from the date Net Sales
       occurred. BD shall have the right, through independent certified public
       accountants acceptable to GNSC, to make an examination, during normal
       business hours, of all records and accounts bearing upon the amount of
       royalty payable to BD hereunder. In the event such examination shows any
       underreporting or underpayment by GNSC in excess of [**] ([**]%) for any
       reporting period, then GNSC shall pay the cost of such examination, the
       amount of any underpaid royalty as well as late payment charges.

   d)  Late payments hereunder shall be subject to a late payment charge
       calculated at an annual rate of [**] percent ([**]%) over the prime rate
       as quoted in the Wall Street Journal on the day payment was due. If the
       amount of such charge exceeds the maximum permitted by law, such charge
       shall be reduced to such maximum.

                                        5
<Page>

8.   CONFIDENTIALITY

   a)  Each party, using the same degree of care used by it to protect its own
       Confidential Information of like character, shall, during the term of
       this Agreement and for a period of five (5) years thereafter, keep
       confidential and not use or disclose, except for the purposes of this
       Agreement, any information relating to the subject matter of this
       Agreement marked conspicuously as "CONFIDENTIAL" at the time of receipt
       from the provider or, if transmitted orally or visually by the provider,
       reduced to writing, marked confidential and provided to recipient within
       thirty (30) days of said oral or visual transfer.

   b)  The foregoing obligations of confidentiality shall not apply to any
       information which:

     i)   Was in the recipients possession prior to acquisition from the
          provider; or

     ii)  Subsequent to receipt by the recipient, is independently developed by
          an employee or agent of recipient who did not have access to such
          information; or

     iii) Is lawfully obtained after the date of this Agreement by the recipient
          from a source other than the provider; or

     iv)  Is generally available to the public or which becomes generally
          lawfully available to the public through sources other than the
          recipient; or

     v)   Is approved for release by written authorization of the provider.

   c)  The terms, but not the existence, of this Agreement shall be treated as
       Confidential Information by the parties, and neither party shall disclose
       the terms or conditions of this Agreement to any third party without the
       prior written permission of the other party. Each party, however, shall
       have the right to make disclosures to the extent required by an order of
       court, regulation of another governmental body, or otherwise by law or by
       a stock exchange, provided that the party shall promptly provide written
       notice to the non-disclosing party of the intended disclosure and of the
       court order or regulation prior to such disclosure and that the party
       takes all reasonable steps to minimize such disclosure by, for example,
       obtaining a protective order and/or appropriate confidentiality
       provisions requiring that such information to be disclosed be used only
       for the purpose for which such law, order, regulation or requirement was
       issued. Additionally, each party may disclose this Agreement or its
       contents to the extent reasonably necessary, under a suitable
       confidentiality agreement, to its accountants, attorneys and financial
       advisors.

9.   TRANSFERABILITY OF RIGHTS AND OBLIGATIONS

   a)  This Agreement and the license granted under it may not be assigned,
       transferred or sold by GNSC.

   b)  BD may freely assign this Agreement in whole or in any part.

                                        6
<Page>

10.  DURATION AND TERMINATION

   a)  The term of this Agreement shall be for two years from the Effective
       Date, unless events occur as set forth in Section 3(f)(ii). This
       Agreement shall automatically renew on an annual basis provided that GNSC
       has Net Sales and has paid to BD royalties due on Net Sales in the
       preceding year.

   b)  BD may terminate this Agreement in the event of a material breach of an
       obligation under this Agreement and GNSC's failure to remedy such breach
       fourteen (14) days after having received notice of such breach.

   c)  In the event that GNSC shall be adjudicated bankrupt, go into
       liquidation, receivership or trusteeship, make an assignment for the
       benefit of its creditors or enter into any similar proceeding of the same
       nature, then BD shall have the right without liability therefore to
       terminate this Agreement forthwith by notice in writing to GNSC. Nothing
       herein shall limit any other remedies to which BD may be entitled to
       under law or equity.

11.  DISCLAIMER AND HOLD HARMLESS

   a)  GNSC agrees to hold BD harmless against judgments, fees, expenses, or
       other costs arising from or incidental to any liability or lawsuit
       brought as a consequence of GNSC's activities under this Agreement,
       whether or not GNSC or any one or more of the employees or agents of GNSC
       is named as a party defendant in any such lawsuit.

   b)  GNSC expressly indemnifies and holds BD, its affiliates, successors and
       assigns and its officers, directors and employees harmless from and
       against any and all claims, liabilities, damages, costs, expenses, and/or
       actions of any kind whatsoever which arise from or are connected with
       GNSC's activities under this Agreement.

   c)  BD makes no representations or warranties of any kind as to the
       merchantability, non-infringement, suitability or safety of Instrument,
       SDA Technology, Licensed Patents, Licensed Know-How or the training
       provided under this Agreement. GNSC shall conduct its own analyses and
       train its own personnel. BD does not confer any right by implication,
       estoppel or otherwise, other than the licenses and rights expressly
       granted herein.

12.  NOTICES

   a)  Any notice or other communication required or permitted by this AGREEMENT
       shall be deemed to have been validly delivered on the date mailed if the
       same shall be mailed by registered or certified mail, postage prepaid,
       return receipt requested, or faxed with confirmation, addressed as
       follows:

     i)   To BD:

       Becton, Dickinson and Company
       7 Loveton Circle

                                        7
<Page>

       Sparks, MD 21152-0999
       Attention: Vice President, Business Development
       Fax No.: (410) 316-4509

       With copy to:

       Becton, Dickinson and Company
       1 Becton Drive, MC089
       Franklin Lakes, NJ  07417-1880
       Attention: Vice President and Chief Intellectual Property Counsel
       Fax No.: (201) 848-9228

    ii)   To GNSC:

       Attention:

13.  GOVERNING LAW

   a)  This Agreement shall be construed, interpreted and applied in accordance
       with and governed by the laws of the state of New Jersey, United States
       of America and the parties hereby submit to the jurisdiction of the
       courts of that state.

14.  SEVERABILITY

   a)  Should any part or provision of this Agreement be held unenforceable or
       in conflict with the law of any jurisdiction, the validity of the
       remaining part or provisions shall not be affected by such holdings.

15.  INFRINGEMENT

   a)  GNSC shall promptly notify BD in writing if GNSC becomes aware of any
       infringement or suspected infringement of any Licensed Patent.

16.  MEDIATION OF DISPUTES

   a)  Either party may give the other party written notice of any dispute
       hereunder not resolved in the normal course of business. If the matter
       has not been resolved within sixty (60) days following such notice, or if
       the parties fail to discuss or meet within twenty-one (21) days following
       such notice, either party may, but shall not be obligated to, initiate
       mediation of the controversy or claim under the then current Center for
       Public Resources Procedure for Mediation of Business Disputes. Once
       mediation is initiated by one party, the other party agrees to
       participate in and conduct the mediation procedures in good faith.

       If  a negotiator intends to be accompanied at a telephone conference or a
       meeting by an attorney, the negotiator for the other party shall be given
       at least three (3) days notice of such intention and may also be
       accompanied by an attorney. All negotiations pursuant to this Section are
       confidential and shall be treated as compromise and settlement

                                        8
<Page>

       negotiations for the purposes of the Federal Rule of Evidence and any
       state rules of evidence.

17.  MISCELLANEOUS

   a)  Nothing herein contained shall be construed to place the parties in the
       relationship of partners or joint venturers or principal and agent or
       create any entity or association, and neither party shall have the power
       to obligate or bind the other in any manner whatsoever.

   b)  Neither party shall use the name of the other or any adaptation thereof
       in any advertising, promotion, sales literature or packaging in a manner
       which would constitute an expressed or implied endorsement for any
       commercial product without prior express written consent.

   c)  Nothing herein contained, whether express or implied, shall be construed
       to grant to GNSC any license or rights in any other of BD's Intellectual
       Property.

   d)  Neither GNSC nor BD shall be responsible for and the terms of this
       Agreement shall be inapplicable to any default or delays which are due to
       cause beyond GNSC'S or BD's control, including but without limitation
       acts of God or of the public enemy, acts or any order of a government,
       fires, floods, or other natural disasters, embargoes, accidents,
       explosions, strikes, or other labor disturbances (regardless of the
       reasonableness of the demands of labor), shortages of fuel, power or raw
       materials, inability to obtain or delays of transportation facilities,
       incidents of war, or other events causing the inability of GNSC or BD,
       acting in good faith with due diligence, to perform its obligations under
       this Agreement.

   e)  This Agreement constitutes the entire agreement between the parties
       hereto with respect to the subject matter hereof, and no modification of
       this Agreement shall be effective unless it is in writing and is signed
       by a duly authorized representative of each party. There are no
       understandings, representations or warranties except as herein expressly
       set forth.

   f)  The failure or delay of a party hereto to enforce any of its rights under
       this Agreement shall not be deemed to be a continuing waiver or a
       modification by such party of any of its rights under this Agreement, and
       a party may, within the time provided by the applicable law, commence
       appropriate legal proceedings to enforce any or all of its rights under
       this Agreement. Any failure to enforce or delay in enforcement shall not
       constitute a defense.

   g)  Neither party shall originate any publicity, news release or public
       announcement, written or oral, whether to the public, press or otherwise,
       relating to this Agreement, to any amendment hereto or performance
       hereunder, without approval of the other party which approval shall not
       be unreasonably withheld, save only such announcement as in the advice of
       counsel to the party making such announcement is required by law to be
       made. In the event GNSC is required by law to disclose this Agreement,
       GNSC shall notify BD in writing within thirty (30) days before making
       such disclosure and GNSC

                                        9
<Page>

       shall make every reasonable effort to only disclose a redacted version of
       the Agreement that is approved in writing by BD.

   h)  BD and GNSC agree to negotiate in good faith to enter into a supply and
       manufacturing arrangement in which BD would provide to GNSC any general
       purpose reagents and analyte specific reagents for the BDProbeTec(TM) ET,
       and in which BD would provide primers, probes and other reagents for
       assay development, as designed and specified by GNSC.

   i)  If GNSC moves forward with a development project for development of a
       test kit which is a Licensed Product, for which FDA clearance or approval
       is required, GNSC agrees to extend to BD the option of working with GNSC
       on that development project. BD must indicate its acceptance of this
       option in writing to GNSC.

   j)  GNSC and BD agree to abide by any and all rules, regulations or laws
       relating to its activities under this Agreement, including, for example,
       the Clinical Laboratory Improvement Amendments of 1988 and the laws
       administered by FDA with regard to the sale of medical devices.

     IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
duly executed in duplicate originals as of the date first hereinabove written.

Becton, Dickinson and Company                Genaissance Pharmaceuticals, Inc.

By:    /s/ L. E. Warfell                     By:   /s/ K. Nandabalan
    --------------------------------             ------------------------------

Name: Larry E. Warfel                        Name: Krishnan Nandabalan
     -------------------------------              -----------------------------

Title: VP, Business Development              Title: VP, Business Development
      ------------------------------               ----------------------------

Date: 12/18/02                               Date: 12/20/02
     -------------------------------              -----------------------------

                                       10
<Page>

                          APPENDIX A: LICENSED PATENTS

   1.  US Patent No. 5,270,184, entitled "Nucleic Acid Target Generation"

   2.  US Patent No. 5,422,252, entitled "Simultaneous Amplification of Multiple
       Targets"

   3.  US Patent No. 5,455,166, entitled "Strand Displacement Amplification"

   4.  US Patent No. 5,536,649, entitled "Decontamination of Nucleic Acid
       Amplification Reactions"

   5.  US Patent No. 5,547,861, entitled "Detection of nucleic acid
       amplification"

   6.  US Patent No. 5,648,211, entitled "Strand Displacement Amplifcation Using
       Thermophilic Enzymes"

   7.  US Patent No. 5,624,825, entitled "Simultaneous Amplification of Multiple
       Targets"

   8.  US Patent No. 5,691,145, entitled "Detection of nucleic acids using
       G-quartets"

   9.  US Patent No. 5,712,124, entitled "Strand Displacement Amplification"

   10. US Patent No. 5,736,365 entitled "Multiplex nucleic acid amplification"

   11. US Patent No. 5,744,311 entitled "Strand displacement amplification using
       thermophilic enzymes"

   12. US Patent No. 5,840,487, entitled "Internal controls for isothermal
       nucleic acid amplification reactions"

   13. US Patent No. 5,863,736, entitled "Method, apparatus and computer program
       products for determining quantities of nucleic acid sequences in samples"

   14. US Patent No. 5,888,739, entitled "Detection of nucleic acids using
       G-quartets and I-tetraplexes"

   15. US Patent No. 5,916,779, entitled "Strand displacement amplification of
       RNA targets"

   16. US Patent No. 5,919,630, entitled "Detection of nucleic acids by
       fluorescence quenching"

   17. US Patent No. 5,928,869, entitled "Detection of nucleic acids by
       fluorescence quenching"

   18. US Patent No. 5,935,791, entitled "Detection of nucleic acids by
       fluorescence quenching"

                                       11
<Page>

   19. US Patent No. 5,958,700, entitled "Detection of nucleic acids by
       fluorescence quenching"

   20. US Patent No. 6,043,880, entitled "Automated optical reader for nucleic
       acid assays"

   21. US Patent No. 6,054,279, entitled "Detection of nucleic acids by
       fluorescence quenching"

   22. US Patent No. 6,066,458, entitled "Methods, apparatus and computer
       program products for determining quantities of nucleic acid sequences in
       samples using standard curves and amplification ratio estimates"

   23. US Patent No. 6,132,684, entitled "Sample tube holder"

   24. US Patent No. 6,216,049, entitled "Computerized method and apparatus for
       analyzing nucleic acid assay readings"

   25. US Patent No. 6,258,546, entitled "Detection of nucleic acid
       amplification"

   26. US Patent No. 6,261,784, entitled "Detection of nucleic acids by strand
       displacement"

   27. US Patent No. 6,316,200, entitled "Probes and methods for detection of
       nucleic acids"

   28. US Patent No. 6,379,888, entitled "Universal probes and methods for
       detection of nucleic acids"

   29. US Patent Application Serial Number [**]

   30. US Patent Application Serial Number [**]

   31. US Patent Application Serial Number [**]

   32. US Patent Application Serial Number [**]

   33. US Patent Application Serial Number [**]

   34. US Patent Application Serial Number [**]

                                       12
<Page>

                                   APPENDIX B

    PROPOSED BDX TRAINING PROGRAM FOR GNSC PERSONNEL AND PRODUCT INFORMATION

A.   Routine training for new BDProbeTec(TM)ET system users through Technical
     ServiceS

             ** CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY
                  WITH THE SECURITIES AND EXCHANGE COMMISSION**

                                       13
<Page>

                              APPPENDIX C: PRODUCTS

                                  [To Be Added]<Page>

                                                                  EXHIBIT 4.10

                          SUPPLEMENTAL INDENTURE NO. 7

                                 by and between

                          HOSPITALITY PROPERTIES TRUST

                                       and

                         U.S. BANK NATIONAL ASSOCIATION

                                   as Trustee

                             as of January 24, 2003

           SUPPLEMENTAL TO THE INDENTURE DATED AS OF FEBRUARY 25, 1998

                      ------------------------------------

                          HOSPITALITY PROPERTIES TRUST

                    6 3/4% Senior Notes due February 15, 2013

<Page>

     This SUPPLEMENTAL INDENTURE NO. 7 (this "Supplemental Indenture") made and
entered into as of January 24, 2003 between HOSPITALITY PROPERTIES TRUST, a
Maryland real estate investment trust (the "Company"), and U.S. BANK NATIONAL
ASSOCIATION, a national banking association (and successor to State Street Bank
and Trust Company ("State Street") in its capacity as Trustee), as Trustee (the
"Trustee").

                                WITNESSETH THAT:

     WHEREAS, the Company and State Street have executed and delivered an
Indenture, dated as of February 25, 1998 (the "Indenture"), relating to the
Company's issuance, from time to time, of various series of debt securities; and

     WHEREAS, U.S. Bank National Association has acquired and succeeded to
substantially all of the corporate trust business of State Street, and, being
eligible to serve as trustee under the Indenture, has succeeded to State Street
as Trustee under the Indenture; and

     WHEREAS, the Company has determined to issue debt securities known as its
6 3/4% Senior Notes due February 15, 2013; and

     WHEREAS, the Indenture provides that certain terms and conditions for each
series of debt securities issued by the Company thereunder may be set forth in
an indenture supplemental to the Indenture;

     NOW, THEREFORE, THIS SUPPLEMENTAL INDENTURE WITNESSETH:

                                    ARTICLE 1

                                  DEFINED TERMS

     Section 1.1 The following definitions supplement, and, to the extent
inconsistent with, replace the definitions in Section 101 of the Indenture:

     "Acquired Debt" means Debt of a Person (i) existing at the time such Person
becomes a Subsidiary or (ii) assumed in connection with the acquisition of
assets from such Person, in each case, other than Debt incurred in connection
with, or in contemplation of, such Person becoming a Subsidiary or such
acquisition. Acquired Debt shall be deemed to be incurred on the date of the
related acquisition of assets from any Person or the date the acquired Person
becomes a Subsidiary.

     "Annual Debt Service" as of any date means the maximum amount which is
expensed in any 12-month period for interest on Debt of the Company and its
Subsidiaries.

     "Business Day" means any day other than a Saturday or Sunday or a day on
which banking institutions in the City of New York or in the city in which the
Corporate Trust Office of the Trustee is located, are required or authorized to
close.

<Page>

     "Capital Stock" means, with respect to any Person, any capital stock
(including preferred stock), shares, interests, participation or other ownership
interests (however designated) of such Person and any rights (other than debt
securities convertible into or exchangeable for capital stock), warrants or
options to purchase any thereof.

     "Consolidated Income Available for Debt Service" for any period means
Earnings from Operations of the Company and its Subsidiaries plus amounts which
have been deducted, and minus amounts which have been added, for the following
(without duplication): (i) interest on Debt of the Company and its Subsidiaries,
(ii) cash reserves made by lessees as required by the Company's leases for
periodic replacement and refurbishment of the Company's assets, (iii) provision
for taxes of the Company and its Subsidiaries based on income, (iv) amortization
of debt discount and deferred financing costs, (v) provisions for gains and
losses on properties and property depreciation and amortization, (vi) the effect
of any noncash charge resulting from a change in accounting principles in
determining Earnings from Operations for such period and (vii) amortization of
deferred charges.

     "Debt" of the Company or any Subsidiary means, without duplication, any
indebtedness of the Company or any Subsidiary, whether or not contingent, in
respect of (i) borrowed money or evidenced by bonds, notes, debentures or
similar instruments, (ii) indebtedness for borrowed money secured by any
Encumbrance existing on property owned by the Company or any Subsidiary, to the
extent of the lesser of (x) the amount of indebtedness so secured and (y) the
fair market value of the property subject to such Encumbrance, (iii) the
reimbursement obligations, contingent or otherwise, in connection with any
letters of credit actually issued (other than letters of credit issued to
provide credit enhancement or support with respect to other indebtedness of the
Company or any Subsidiary otherwise reflected as Debt hereunder) or amounts
representing the balance deferred and unpaid of the purchase price of any
property or services, except any such balance that constitutes an accrued
expense or trade payable, or all conditional sale obligations or obligations
under any title retention agreement, (iv) the principal amount of all
obligations of the Company or any Subsidiary with respect to redemption,
repayment or other repurchase of any Disqualified Stock, or (v) any lease of
property by the Company or any Subsidiary as lessee which is reflected on the
Company's consolidated balance sheet as a capitalized lease in accordance with
GAAP, to the extent, in the case of items of indebtedness under (i) through
(iii) above, that any such items (other than letters of credit) would appear as
a liability on the Company's consolidated balance sheet in accordance with GAAP,
and also includes, to the extent not otherwise included, any obligation by the
Company or any Subsidiary to be liable for, or to pay, as obligor, guarantor or
otherwise (other than for purposes of collection in the ordinary course of
business), Debt of another Person (other than the Company or any Subsidiary) (it
being understood that Debt shall be deemed to be incurred by the Company or any
Subsidiary whenever the Company or such Subsidiary shall create, assume,
guarantee or otherwise become liable in respect thereof).

     "Disqualified Stock" means, with respect to any Person, any Capital Stock
of such Person which by the terms of such Capital Stock (or by the terms of any
security into which it is convertible or for which it is exchangeable or
exercisable), upon the happening of any event or otherwise (i) matures or is
mandatorily redeemable, pursuant to a sinking fund obligation or

                                        2
<Page>

otherwise (other than Capital Stock which is redeemable solely in exchange for
common stock or shares), (ii) is convertible into or exchangeable or exercisable
for Debt or Disqualified Stock, or (iii) is redeemable at the option of the
holder thereof, in whole or in part (other than Capital Stock which is
redeemable solely in exchange for common stock or shares), in each case on or
prior to the stated maturity of the Notes.

     "Earnings from Operations" for any period means net earnings excluding
gains and losses on sales of investments, extraordinary items, gains and losses
from early extinguishment of debt and property valuation losses, as reflected in
the financial statements of the Company and its Subsidiaries for such period,
determined on a consolidated basis in accordance with GAAP.

     "Encumbrance" means any mortgage, lien, charge, pledge or security interest
of any kind.

     "Make-Whole Amount" means, in connection with any optional redemption or
accelerated payment of any Notes prior to August 15, 2012, the excess, if any,
of (i) the aggregate present value as of the date of such redemption or
accelerated payment of each dollar of principal being redeemed or paid and the
amount of interest (exclusive of interest accrued to the date of redemption or
accelerated payment) that would have been payable in respect of such dollar if
such redemption or accelerated payment had been made on August 15, 2012,
determined by discounting, on a semiannual basis, such principal and interest at
the Reinvestment Rate (determined on the third Business Day preceding the date
such notice of redemption is given or declaration of acceleration is made) from
the respective dates on which such principal and interest would have been
payable if such redemption or accelerated payment had been made on August 15,
2012, over (ii) the aggregate principal amount of the Notes being redeemed or
paid. In the case of any redemption or accelerated payment of notes on or after
August 15, 2012, the Make-Whole Amount means zero. For purposes of this
Supplemental Indenture and the Notes, references in the Indenture to the payment
of the principal (and premium, if any) and interest on the Notes shall be deemed
to include the payment of the Make-Whole Amount, if any, due upon redemption
with respect to the Notes. The Make-Whole Amount shall be calculated by the
Company and set forth in an Officer's Certificate delivered to the Trustee, and
the Trustee shall be entitled to rely on said Officer's Certificate.

     "Notes" means the Company's 6 3/4% Senior Notes due February 15, 2013,
issued under this Supplemental Indenture and the Indenture, as amended or
supplemented from time to time.

     "Reinvestment Rate" means a rate per annum equal to the sum of 0.50% (fifty
one hundredths of one percent) plus the yield on treasury securities at constant
maturity under the heading "Week Ending" published in the Statistical Release
under the caption "Treasury Constant Maturities" for the maturity (rounded to
the nearest month) corresponding to the remaining life to maturity (which, the
case of maturities corresponding to the principal and interest due on the notes
at their maturity, shall be deemed to be August 15, 2012), as of the payment
date of the principal being redeemed or paid. If no maturity exactly corresponds
to such maturity, yields for the two published maturities most closely
corresponding to such maturity shall be calculated pursuant to the immediately
preceding sentence and the Reinvestment Rate shall be interpolated or
extrapolated from such yields on a straight-line basis,

                                        3
<Page>

rounding in each of such relevant periods to the nearest month. For purposes of
calculating the Reinvestment Rate, the most recent Statistical Release published
prior to the date of determination of the Make-Whole Amount shall be used.

     "Secured Debt" means Debt secured by any mortgage, lien, charge, pledge or
security interest of any kind.

     "Statistical Release" means the statistical release designated "H.15(519)"
or any successor publication which is published weekly by the Federal Reserve
System and which establishes yields on actively traded United States government
securities adjusted to constant maturities or, if such statistical release is
not published at the time of any determination under this Supplemental
Indenture, then any publicly available source of similar market data which shall
be designated by the Company.

     "Subsidiary" means any corporation or other entity of which a majority of
(i) the voting power of the voting equity securities or (ii) the outstanding
equity interests of which are owned, directly or indirectly, by the Company or
one or more other Subsidiaries of the Company. For the purposes of this
definition, "voting equity securities" means equity securities having voting
power for the election of directors, whether at all times or only so long as no
senior class of security has such voting power by reason of any contingency.

     "Total Assets" as of any date means the sum of (i) the Undepreciated Real
Estate Assets and (ii) all other assets of the Company and its Subsidiaries
determined in accordance with GAAP (but excluding accounts receivable and
intangibles).

     "Total Unencumbered Assets" means the sum of (i) those Undepreciated Real
Estate Assets not subject to an Encumbrance for borrowed money and (ii) all
other assets of the Company and its Subsidiaries not subject to an Encumbrance
for borrowed money determined in accordance with GAAP (but excluding accounts
receivable and intangibles).

     "Undepreciated Real Estate Assets" as of any date means the cost (original
cost plus capital improvements) of real estate assets of the Company and its
Subsidiaries on such date, before depreciation and amortization determined on a
consolidated basis in accordance with GAAP.

     "Unsecured Debt" means Debt which is not secured by any of the properties
of the Company or any Subsidiary.

                                    ARTICLE 2

                               TERMS OF THE NOTES

     Section 2.1 Pursuant to Section 301 of the Indenture, the Notes shall have
the following terms and conditions:

                                        4
<Page>

     (a)    Title; Limitation on Aggregate Principal Amount; Form of Notes. The
Notes shall be Registered Securities under the Indenture and shall be known as
the Company's "6 3/4% Senior Notes due February 15, 2013." The aggregate
principal amount of Notes which may be authenticated and delivered under this
Indenture Supplement shall not, except as permitted by the provisions of the
Indenture, exceed $175,000,000 provided that the Company may, without the
consent of the holders of the Notes, reopen this series and issue additional
Notes under the Indenture and this Indenture Supplement in addition to the
$175,000,000 of Notes authorized as of the date hereof. The Notes (together with
the Trustee's certificate of authentication) shall be substantially in the form
of Exhibit A hereto, which is hereby incorporated in and made a part of this
Supplemental Indenture.

     The Notes will be issued in the form of one or more registered global
securities without coupons ("Global Notes") which will be deposited with, or on
behalf of, The Depository Trust Company ("DTC"), and registered in the name of
DTC's nominee, Cede & Co. Except under the circumstance described below, the
Notes will not be issuable in definitive form. Unless and until it is exchanged
in whole or in part for the individual notes represented thereby, a Global Note
may not be transferred except as a whole by DTC to a nominee of DTC or by a
nominee of DTC to DTC or another nominee of DTC or by DTC or any nominee of DTC
to a successor depositary or any nominee of such successor.

     So long as DTC or its nominee is the registered owner of a Global Note, DTC
or such nominee, as the case may be, will be considered the sole owner or holder
of the Notes represented by such Global Note for all purposes under this
Supplemental Indenture. Except as described below, owners of beneficial interest
in Notes evidenced by a Global Note will not be entitled to have any of the
individual Notes represented by such Global Note registered in their names, will
not receive or be entitled to receive physical delivery of any such Notes in
definitive form and will not be considered the owners or holders thereof under
the Indenture or this Supplemental Indenture.

     If DTC is at any time unwilling, unable or ineligible to continue as
depositary and a successor depositary is not appointed by the Company within 90
days, the Company will issue individual Notes in exchange for the Global Note or
Global Notes representing such Notes. In addition, the Company may at any time
and in its sole discretion, subject to certain limitations set forth in the
Indenture, determine not to have any of such Notes represented by one or more
Global Notes and, in such event, will issue individual Notes in exchange for the
Global Note or Global Notes representing the Notes. Individual Notes so issued
will be issued in denominations of $1,000 and integral multiples thereof.

     (b)    Interest and Interest Rate. The Notes will bear interest at a rate
of 6 3/4% per annum, from January 24, 2003 (or, in the case of Notes issued upon
the reopening of this series of Notes, from the date designated by the Company
in connection with such reopening) or from the immediately preceding Interest
Payment Date to which interest has been paid or duly provided for, payable
semi-annually in arrears on February 15 and August 15 of each year, commencing
August 15, 2003 or if such day is not a Business Day (as defined in the
Indenture), on the next succeeding Business Day (each of which shall be an
"Interest Payment Date"), to the Persons in

                                        5
<Page>

whose names the Notes are registered in the Security Register at the close of
business on the day falling 14 calendar days immediately preceding the
applicable interest payment date (whether or not a Business Day), as the case
may be (each, a "Regular Record Date").

     (c)    Principal Repayment; Currency. The stated maturity of the Notes is
February 15, 2013, provided, however, the Notes may be earlier redeemed at the
option of the Company as provided in paragraph (d) below. The principal of each
Note payable on its maturity date shall be paid against presentation and
surrender thereof at the Corporate Trust Office of the Trustee, located
initially at Two Avenue de Lafayette, Boston, Massachusetts 02111, in such coin
or currency of the United States of America as at the time of payment is legal
tender for the payment of public or private debts. The Company will not pay
Additional Amounts (as defined in the Indenture) on the Notes.

     (d)    Redemption at the Option of the Company. The Notes will be subject
to redemption at any time at the option of the Company, in whole or in part,
upon not less than 30 nor more than 60 days' notice to each Holder of Notes to
be redeemed at its address appearing in the Security Register, at a price equal
to the sum of (i) the principal amount of the Notes being redeemed, plus accrued
and unpaid interest to but excluding the applicable Redemption Date, plus (ii)
the Make-Whole Amount, if any. If the notes are redeemed on or after August 15,
2012, the redemption price will not include the Make-Whole Amount.

     (e)    Notices. All notices and other communications hereunder shall be in
writing and shall be deemed to have been duly given if mailed or transmitted by
any standard form of telecommunication. Notices to the Company shall be directed
to it at 400 Centre Street, Newton, Massachusetts 02458, Attention: President;
notices to the Trustee shall be directed to it at Two Avenue de Lafayette,
Boston, Massachusetts 02111, Attention: Corporate Trust Department, Re:
Hospitality Properties Trust 6 3/4% Senior Notes due February 15, 2013, or as to
either party, at such other address as shall be designated by such party in a
written notice to the other party.

     (f)    Global Note Legend. Each Global Note shall bear the following legend
on the face thereof:

     UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE
DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION ("DTC"), TO THE ISSUER OR ITS
AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE
ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS IS
REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO
CEDE & CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED
REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR
OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE REGISTERED OWNER
HEREOF, CEDE & CO., HAS AN INTEREST HEREIN.

                                        6
<Page>

     (g)    Applicability of Discharge, Defeasance and Covenant Defeasance
Provisions. The Discharge, Defeasance and Covenant Defeasance provisions in
Article Fourteen of the Indenture will apply to the Notes.

                                    ARTICLE 3

                              ADDITIONAL COVENANTS

     Section 3.1 In addition to the covenants of the Company set forth in
Article Ten of the Indenture, for the benefit of the holders of the Notes:

     (a)    Limitations on Incurrence of Debt.

     (i)    The Company will not, and will not permit any Subsidiary to, incur
any Debt if, immediately after giving effect to the incurrence of such
additional Debt and the application of the proceeds thereof, the aggregate
principal amount of all outstanding Debt of the Company and its Subsidiaries on
a consolidated basis determined in accordance with GAAP is greater than 60% of
the sum ("Adjusted Total Assets") of (without duplication) (i) the Total Assets
of the Company and its Subsidiaries as of the end of the calendar quarter
covered in the Company's Annual Report on Form 10-K, or the Quarterly Report on
Form 10-Q, as the case may be, most recently filed with the Securities and
Exchange Commission (or, if such filing is not permitted under the Securities
Exchange Act of 1934, as amended (the "Exchange Act"), with the Trustee) prior
to the incurrence of such additional Debt and (ii) the purchase price of any
real estate assets or mortgages receivable acquired, and the amount of any
securities offering proceeds received (to the extent that such proceeds were not
used to acquire real estate assets or mortgages receivable or used to reduce
Debt), by the Company or any Subsidiary since the end of such calendar quarter,
including those proceeds obtained in connection with the incurrence of such
additional Debt.

     (ii)   In addition to the foregoing limitations on the incurrence of Debt,
the Company will not, and will not permit any Subsidiary to, incur any Secured
Debt if, immediately after giving effect to the incurrence of such additional
Secured Debt and the application of the proceeds thereof, the aggregate
principal amount of all outstanding Secured Debt of the Company and its
Subsidiaries on a consolidated basis is greater than 40% of Adjusted Total
Assets.

     (iii)  In addition to the foregoing limitations on the incurrence of Debt,
the Company will not, and will not permit any Subsidiary to, incur any Debt if
the ratio of Consolidated Income Available for Debt Service to the Annual Debt
Service for the four consecutive fiscal quarters most recently ended prior to
the date on which such additional Debt is to be incurred shall have been less
than 1.5x, on a pro forma basis after giving effect thereto and to the
application of the proceeds therefrom, and calculated on the assumption that (i)
such Debt and any other Debt incurred by the Company and its Subsidiaries since
the first day of such four-quarter period and the application of the proceeds
therefrom, including to refinance other Debt, had occurred at the beginning of
such period; (ii) the repayment or retirement of any other Debt by the Company
and its Subsidiaries since the first date of such four-quarter period had been
repaid or retired at the

                                        7
<Page>

beginning of such period (except that, in making such computation, the amount of
Debt under any revolving credit facility shall be computed based upon the
average daily balance of such Debt during such period); (iii) in the case of
Acquired Debt or Debt incurred in connection with any acquisition since the
first day of such four-quarter period, the related acquisition had occurred as
of the first day of such period with appropriate adjustments with respect to
such acquisition being included in such pro forma calculation; and (iv) in the
case of any acquisition or disposition by the Company or its Subsidiaries of any
asset or group of assets since the first day of such four-quarter period,
whether by merger, stock purchase or sale, or asset purchase or sale, such
acquisition or disposition or any related repayment of Debt had occurred as of
the first day of such period with the appropriate adjustments with respect to
such acquisition or disposition being included in such pro forma calculation. If
the Debt giving rise to the need to make the foregoing calculation or any other
Debt incurred after the first day of the relevant four-quarter period bears
interest at a floating rate then, for purposes of calculating the Annual Debt
Service, the interest rate on such Debt shall be computed on a pro forma basis
as if the average interest rate which would have been in effect during the
entire such four-quarter period had been the applicable rate for the entire such
period.

     (b)    Maintenance of Total Unencumbered Assets. The Company and its
Subsidiaries will maintain at all times Total Unencumbered Assets of not less
than 200% of the aggregate outstanding principal amount of the Unsecured Debt of
the Company and its Subsidiaries on a consolidated basis.

                                    ARTICLE 4

                          ADDITIONAL EVENTS OF DEFAULT

     Section 4.1 For purposes of this Supplemental Indenture and the Notes, in
addition to the Events of Default set forth in Section 501 of the Indenture, it
shall also constitute an "Event of Default" if a default under any bond,
debenture, note or other evidence of indebtedness of the Company (including a
default with respect to any other series of securities), or under any mortgage,
indenture or other instrument of the Company under which there may be issued or
by which there may be secured or evidenced any indebtedness for money borrowed
by the Company (or by any Subsidiary, the repayment of which the Company has
guaranteed or for which the Company is directly responsible or liable as obligor
or guarantor) having an aggregate principal amount outstanding of at least
$20,000,000, whether such indebtedness now exists or shall hereafter be incurred
or created, which default shall have resulted in such indebtedness becoming or
being declared due and payable prior to the date on which it would otherwise
have become due and payable, without such indebtedness having been discharged or
such acceleration having been rescinded or annulled within a period of ten days
after there shall have been given, by registered or certified mail, to the
Company by the Trustee or to the Company and the Trustee by the Holders of at
least 25% in principal amount of the outstanding Notes, a written notice
specifying such default and requiring the Company to cause such indebtedness to
be discharged or cause such acceleration to be rescinded or annulled and stating
that such notice is a "Notice of Default" hereunder.

                                        8
<Page>

     Section 4.2 Notwithstanding any provisions to the contrary in the
Indenture, upon any acceleration of the Notes under Section 502 of the
Indenture, the amount immediately due and payable in respect of the Notes shall
equal the Outstanding principal amount thereof, plus accrued interest, plus, if
such acceleration occurs prior to August 15, 2012, the Make-Whole Amount.

                                    ARTICLE 5

                                  EFFECTIVENESS

     This Supplemental Indenture shall be effective for all purposes as of the
date and time this Supplemental Indenture has been executed and delivered by the
Company and the Trustee in accordance with Article Nine of the Indenture. As
supplemented hereby, the Indenture is hereby confirmed as being in full force
and effect.

                                    ARTICLE 6

                                  MISCELLANEOUS

     Section 6.1 In the event any provision of this Supplemental Indenture shall
be held invalid or unenforceable by any court of competent jurisdiction, such
holding shall not invalidate or render unenforceable any other provision hereof
or any provision of the Indenture.

     Section 6.2 To the extent that any terms of this Supplemental Indenture or
the Notes are inconsistent with the terms of the Indenture, the terms of this
Supplemental Indenture or the Notes shall govern and supersede such inconsistent
terms.

     Section 6.3 This Supplemental Indenture shall be governed by and construed
in accordance with the laws of The Commonwealth of Massachusetts.

     Section 6.4 This Supplemental Indenture may be executed in several
counterparts, each of which shall be an original and all of which shall
constitute but one and the same instrument.

                                        9
<Page>

     IN WITNESS WHEREOF, the Company and the Trustee have caused this
Supplemental Indenture to be executed as an instrument under seal in their
respective corporate names as of the date first above written.

                                        HOSPITALITY PROPERTIES TRUST

                                        By: /s/ John G. Murray
                                            Name: John G. Murray
                                            Title: President

                                        U.S. BANK NATIONAL ASSOCIATION, as
                                          Trustee

                                        By: /s/ Paul D. Allen
                                            Name:  Paul D. Allen
                                            Title: Vice President

                                       10
<Page>

                                                                       EXHIBIT A

                                 (Face of Note)

                    6 3/4% Senior Note due February 15, 2013

No.                                                                 $__________

                          HOSPITALITY PROPERTIES TRUST

promises to pay to _______________________________________ or registered
assigns, the principal sum of __________ ($_______) on February 15, 2013,
subject to the terms set forth on the reverse of this Note and the terms of the
Indenture referred to therein.

Interest Payment Dates:  February 15 and August 15,  commencing August 15, 2003.
Record  Dates:  the day falling 14 calendar  days prior to any Interest  Payment
Date.

CUSIP No:  _____________

                                        HOSPITALITY PROPERTIES TRUST

                                        By:
                                           ------------------------------
                                           Name:

                                           Title:

Dated:

This is one of the Notes referred to in the within-mentioned Indenture:

U.S. BANK NATIONAL ASSOCIATION, as Trustee

By:
   ------------------------------
    Authorized Officer

                                       A-1
<Page>

             [THE FOLLOWING CONSTITUTES THE REVERSE OF THE SECURITY]

                          HOSPITALITY PROPERTIES TRUST

                    6 3/4% Senior Note due February 15, 2013

     Capitalized terms used herein have the meanings assigned to them in the
Indenture (as defined below) unless otherwise indicated.

     1.     Interest. Hospitality Properties Trust, a Maryland real estate
investment trust (the "Company"), promises to pay interest on the principal
amount of this Note at the rate and in the manner specified below.

     The Company shall pay in cash interest on the principal amount of this Note
at the rate per annum of 6 3/4%. The Company will pay interest semi-annually in
arrears on February 15 and August 15 of each year, commencing on August 15, 2003
or if any such day is not a Business Day (as defined in the Indenture), on the
next succeeding Business Day (each an "Interest Payment Date"), to Holders of
record on the day falling 14 calendar days immediately preceding such Interest
Payment Date (whether or not a Business Day).

     Interest will be computed on the basis of a 360-day year consisting of
twelve 30-day months. Interest shall accrue from the most recent date to which
interest has been paid or, if no interest has been paid, from the date of the
original issuance of the Notes.

     2.     Method of Payment. The Company will pay interest on the Notes
(except defaulted interest) to the Persons who are registered Holders of Notes
at the close of business on the record date next preceding the Interest Payment
Date, even if such Notes are canceled after such record date and on or before
such Interest Payment Date. The Company will pay principal and interest in money
of the United States that at the time of payment is legal tender for payment of
public and private debts. The Company, however, may pay principal, premium, if
any, and interest by check payable in such money. It may mail an interest check
to a Holder's registered address.

     3.     Indenture. The Company issued the Notes under an Indenture dated as
of February 25, 1998 and Supplemental Indenture No. 7 dated as of January 24,
2003 (collectively, the "Indenture") between the Company and the Trustee. The
terms of the Notes include those stated in the Indenture and those made part of
the Indenture by reference to the Trust Indenture Act of 1939 (15 U.S. Code
secs. 77aaa-77bbbb) as in effect on the date of the Indenture. The Notes are
subject to all such terms, and Holders of the Notes are referred to the
Indenture and such Act for a statement of such terms. The terms of the Indenture
shall govern any inconsistencies between the Indenture and the Notes. The Notes
are unsecured general obligations of the Company initially issued in an
aggregate principal amount of $175,000,000.

     4.     Optional Redemption. The Notes will be subject to redemption at any
time at the option of the Company, in whole or in part, upon not less than 30
nor more than 60 days' notice, at a redemption price equal to the sum of (i) the
principal amount of the Notes being redeemed,

                                       A-2
<Page>

plus accrued and unpaid interest to but excluding the applicable Redemption Date
and (ii) the Make-Whole Amount.

     As used herein the term "Make-Whole Amount" means, in connection with any
optional redemption or accelerated payment of any notes prior to August 15,
2012, the excess, if any, of (i) the aggregate present value as of the date of
such redemption or accelerated payment of each dollar of principal being
redeemed or paid and the amount of interest (exclusive of interest accrued to
the date of redemption or accelerated payment) that would have been payable in
respect of such dollar if such redemption or accelerated payment had been made
on August 15, 2012, determined by discounting, on a semiannual basis, such
principal and interest at the Reinvestment Rate (determined on the third
Business Day preceding the date such notice of redemption is given or
declaration of acceleration is made) from the respective dates on which such
principal and interest would have been payable if such redemption or accelerated
payment had been made on August 15, 2012, over (ii) the aggregate principal
amount of the Notes being redeemed or paid. In the case of any redemption or
accelerated payment of notes on or after August 15, 2012, the Make-Whole Amount
means zero. For purposes of the Indenture and the Notes, references in the
Indenture to the payment of the principal (and premium, if any) and interest on
the Notes shall be deemed to include the payment of the Make-Whole Amount, if
any, due upon redemption with respect to the Notes. The Make-Whole Amount shall
be calculated by the Company and set forth in an Officer's Certificate delivered
to the Trustee, and the Trustee shall be entitled to rely on said Officer's
Certificate.

     As used herein the term "Reinvestment Rate" means a rate per annum equal to
the sum of 0.50% (fifty one hundredths of one percent) plus the yield on
treasury securities at constant maturity under the heading "Week Ending"
published in the Statistical Release (as defined herein) under the caption
"Treasury Constant Maturities" for the maturity (rounded to the nearest month)
corresponding to the remaining life to maturity (which, in the case of
maturities corresponding to the principal and interest due on the notes at their
maturity, shall be deemed to be August 15, 2012), as of the payment date of the
principal being redeemed or paid. If no maturity exactly corresponds to such
maturity, yields for the two published maturities most closely corresponding to
such maturity shall be calculated pursuant to the immediately preceding sentence
and the Reinvestment Rate shall be interpolated or extrapolated from such yields
on a straight-line basis, rounding in each of such relevant periods to the
nearest month. For purposes of calculating the Reinvestment Rate, the most
recent Statistical Release published prior to the date of determination of the
Make-Whole Amount shall be used.

     As used herein the term "Statistical Release" means the statistical release
designated "H.15(519)" or any successor publication which is published weekly by
the Federal Reserve System and which establishes yields on actively traded
United States government securities adjusted to constant maturities or, if such
statistical release is not published at the time of any determination under the
Supplemental Indenture, then any publicly available source of similar market
data which shall be designated by the Company.

     5.     Mandatory Redemption. The Company shall not be required to make
sinking fund or redemption payments with respect to the Notes.

                                       A-3
<Page>

     6.     Notice of Redemption. Notice of redemption shall be mailed at least
30 days but not more than 60 days before the Redemption Date to each Holder of
Notes to be redeemed at its registered address. Notes may be redeemed in part
but only in whole multiples of $1,000, unless all of the Notes held by a Holder
are to be redeemed. On and after the redemption date, interest ceases to accrue
on Notes or portions of them called for redemption.

     7.     Denominations, Transfer, Exchange. The Notes are in registered form
without coupons in denominations of $1,000 and integral multiples of $1,000 in
excess thereof. The transfer of Notes may be registered and Notes may be
exchanged as provided in the Indenture. The Security Registrar and the Trustee
may require a Holder, among other things, to furnish appropriate endorsements
and transfer documents and to pay any taxes and fees required by law or
permitted by the Indenture. The Security Registrar need not exchange or register
the transfer of any Note or portion of a Note selected for redemption. Also, it
need not exchange or register the transfer of any Notes for a period of 15 days
before the mailing of a notice of redemption of Notes, or during the period
between a record date and the corresponding Interest Payment Date.

     8.     Defaults and Remedies. In case an Event of Default (as defined in
the Indenture) with respect to the Notes shall have occurred and be continuing,
the principal hereof may be declared, and upon such declaration shall become,
due and payable, in the manner, with the effect and subject to the provisions
provided in the Indenture.

     9.     Actions of Holders. The Indenture contains provisions permitting the
holders of not less than a majority of the aggregate principal amount of the
outstanding Notes, subject to certain exceptions as provided in the Indenture,
on behalf of the holders of all such Notes at a meeting duly called and held as
provided in the Indenture, to make, give or take any request, demand,
authorization, direction, notice, consent, waiver or other action provided in
the Indenture to be made, given or taken by the holders of the Notes, including
without limitation, waiving (a) compliance by the Company with certain
provisions of the Indenture, and (b) certain past defaults under the Indenture
and their consequences. Any resolution passed or decision taken at any meeting
of the holders of the Notes in accordance with the provisions of the Indenture
shall be conclusive and binding upon such holders and upon all future holders of
this Note and other Notes issued upon the registration of transfer hereof or in
exchange heretofore or in lieu hereof.

     10.    Persons Deemed Owners. The Company, the Trustee, and any agent of
the Company or the Trustee may deem and treat the Person in whose name this Note
is registered on the Security Register as its absolute owner for all purposes.

     11.    Authentication. This Note shall not be valid until authenticated by
the manual signature of the Trustee or an authenticating agent.

     12.    Governing Law. THE INTERNAL LAW OF THE COMMONWEALTH OF MASSACHUSETTS
SHALL GOVERN AND BE USED TO CONSTRUE THE INDENTURE AND THE NOTES.

                                       A-4
<Page>

     13.    No Personal Liability. THE DECLARATION OF TRUST OF THE COMPANY,
AMENDED AND RESTATED ON AUGUST 21, 1995, A COPY OF WHICH, TOGETHER WITH ALL
AMENDMENTS THERETO (THE "DECLARATION"), IS DULY FILED IN THE OFFICE OF THE
DEPARTMENT OF ASSESSMENTS AND TAXATION OF THE STATE OF MARYLAND, PROVIDES THAT
THE NAME "HOSPITALITY PROPERTIES TRUST" REFERS TO THE TRUSTEES UNDER THE
DECLARATION COLLECTIVELY AS TRUSTEES, BUT NOT INDIVIDUALLY OR PERSONALLY, AND
THAT NO TRUSTEE, OFFICER, SHAREHOLDER, EMPLOYEE OR AGENT OF THE COMPANY SHALL BE
HELD TO ANY PERSONAL LIABILITY, JOINTLY OR SEVERALLY, FOR ANY OBLIGATION OF, OR
CLAIM AGAINST, THE COMPANY. ALL PERSONS DEALING WITH THE COMPANY, IN ANY WAY,
SHALL LOOK ONLY TO THE ASSETS OF THE COMPANY FOR THE PAYMENT OF ANY SUM OR THE
PERFORMANCE OF ANY OBLIGATION.

     The Company will furnish to any Holder upon written request and without
charge a copy of the Indenture. Request may be made to:

                          Hospitality Properties Trust
                          400 Centre Street
                          Newton, MA 02458
                          Telecopier No.:  (617) 964-8389
                          Attention: President

                                       A-5
<Page>

                                 ASSIGNMENT FORM

                  To assign this Note, fill in the form below:

[I] [We] assign and transfer this Note to ____________________________________
__________________________________ [Print or type assignee's name, address and
zip code] _________________________ [Insert assignee's soc. sec. or tax I.D.
no.] and irrevocably appoint_____________________________ to transfer this Note
on the books of the Company. The agent may substitute another to act for him.

Date:
      --------------

                                        Your Signature:

                                        ----------------------------------
                                        [Sign exactly as your name appears
                                        on the face of this Note]

Signature Guarantee:

-----------------------------
[The signature must be guaranteed
by an officer of a participant
in a recognized signature guarantee
program. Notarized or witnessed
signatures are not acceptable.]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00050-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00050-of-00352.parquet"}]]